Anna Candoni
A5003619706- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Antifungal resistance and susceptibility
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Fungal Infections and Studies
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Histone Deacetylase Inhibitors Research
- Hematopoietic Stem Cell Transplantation
- Infectious Diseases and Mycology
- Retinoids in leukemia and cellular processes
- Pneumocystis jirovecii pneumonia detection and treatment
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Eosinophilic Disorders and Syndromes
- SARS-CoV-2 and COVID-19 Research
- Drug Transport and Resistance Mechanisms
- Childhood Cancer Survivors' Quality of Life
- COVID-19 and healthcare impacts
- Antibiotic Resistance in Bacteria
- Kruppel-like factors research
- COVID-19 Clinical Research Studies
- Cancer Treatment and Pharmacology
University of Modena and Reggio Emilia
2023-2025
Azienda Ospedaliero-Universitaria di Modena
2024-2025
Ospedale Santa Maria della Misericordia di Udine
2015-2024
University of Udine
2014-2024
Azienda Unità Sanitaria Locale di Ferrara
2021-2024
Azienda Sanitaria Universitaria Integrata di Trieste
2016-2023
Ospedale Antonio Cardarelli
2022
John Wiley & Sons (United States)
2020
Hudson Institute
2020
Azienda Ospedaliera S.Maria
2012-2017
Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance aimed to collect data from adult who required hospitalisation for COVID-19.This multicentre, retrospective, cohort study included (aged ≥18 years) diagnosis of WHO-defined malignancy admitted 66 hospitals between Feb 25 May 18, 2020, laboratory-confirmed symptomatic COVID-19. Data cutoff analysis was June 22, 2020. primary...
The purpose of our study was to evaluate the incidence and outcome invasive fungal infection (IFI) among patients who underwent autologous or allogeneic hematopoietic stem cell transplantation (HSCT) at 11 Italian centers.This cohort-retrospective study, conducted during 1999-2003, involved HSCT admitted tertiary care centers university hospitals in Italy, developed IFIs (proven probable).Among 3228 (1249 recipients 1979 recipients), IFI occurred 121 (overall incidence, 3.7%). Ninety-one...
Background The aim of this study was to evaluate prognostic factors, treatments and outcome invasive aspergillosis in patients with acute myeloid leukemia based on data collected a registry.Design Methods registry, which activated 2004 closed 2007, leukemia, admitted 21 hematologic divisions tertiary care centers or university hospitals Italy, who developed proven probable aspergillosis.Results One hundred forty cases were collected, most occurring during the period post-induction aplasia,...
Menin inhibitors are new and promising agents currently in clinical development that target the HOX/MEIS1 transcriptional program which is critical for leukemogenesis histone-lysine N-methyltransferase 2A-rearranged (KMT2Ar) NPM1-mutated (NPM1mut) acute leukemias. The mechanism of action this class based on disruption menin-KMT2A complex (consisting chromatin remodeling proteins), leading to differentiation apoptosis AML cells expressing KMT2A or with mutated NPM1. To date, drugs has been...
This Phase 1B study showed that a single tablet of 300 mg posaconazole, given once daily as prophylaxis to 210 patients at risk for invasive fungal disease, was safe reported posaconazole oral suspension and achieved steady-state >500 ng/mL all but one patient.
Gram-negative bacteremia (GNB) is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), updated epidemiological investigation advisable.We prospectively evaluated the epidemiology pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) 1625 autologous (auto-HSCTs) among 54 transplant centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression methods. we identified risk factors for impact on 4-month overall-survival transplant.The cumulative...
The aim of this study was to identify risk factors for mortality in patients suffering from hematological malignancies (HMs) with bloodstream infections (BSIs) caused by Klebsiella pneumoniae (KP). We conducted a prospective cohort on KP BSI 13 Italian units participating the HEMABIS registry-SEIFEM group. outcome measured death within 21 days onset. Survivor and non-survivor subgroups were compared Cox regression analysis independent predictors mortality. A total 278 episodes included...
The treatment of choice in steroid-resistant immune thrombocytopenia is still controversial due to the recent advent new drugs (anti-CD20 antibodies and thrombopoietin mimetics) that have encouraged a generalized tendency delay splenectomy. Consequently, it extremely importance define efficacy safety splenectomy long term. We retrospectively analyzed data 233 patients affected by who underwent between 1959 2001 6 European hematologic institutions now minimum follow up ten years from surgery....
Therapy-related myeloid neoplasms (t-MN) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. We report data on 277 t-MN patients, recruited between 1999 2013 by the Italian Network Secondary Leukemias (104 retrospectively 173 prospectively registered). Median age at diagnosis was 64 years (range, 21-87). Most frequent malignancies (PMs) were lymphoproliferative diseases breast cancer. One hundred thirty-three patients had received chemotherapy (CHT), 43...
Summary COVID‐19 is associated with high mortality in patients haematological malignancies (HM) and rate of seroconversion unknown. The ITA‐HEMA‐COV project (NCT04352556) investigated patterns for SARS‐CoV‐2 IgG HMs. A total 237 patients, PCR‐positive at least one test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid 54 (22·8%) plasma cell neoplasms. Overall, 69% (164 237) detectable serum antibodies. Serologically negative (31%, 73...